Vestal Point Capital LP Purchases New Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Vestal Point Capital LP bought a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 525,000 shares of the company's stock, valued at approximately $6,122,000. Vestal Point Capital LP owned about 0.52% of Intellia Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Squarepoint Ops LLC grew its stake in Intellia Therapeutics by 58.8% in the 4th quarter. Squarepoint Ops LLC now owns 101,417 shares of the company's stock valued at $1,183,000 after buying an additional 37,533 shares during the last quarter. Two Sigma Advisers LP grew its stake in Intellia Therapeutics by 94.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company's stock valued at $23,300,000 after buying an additional 970,700 shares during the last quarter. Two Sigma Investments LP grew its stake in Intellia Therapeutics by 88.1% in the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company's stock valued at $21,498,000 after buying an additional 863,363 shares during the last quarter. Teza Capital Management LLC grew its stake in Intellia Therapeutics by 74.3% in the 4th quarter. Teza Capital Management LLC now owns 26,065 shares of the company's stock valued at $304,000 after buying an additional 11,107 shares during the last quarter. Finally, Tema Etfs LLC acquired a new position in Intellia Therapeutics in the 4th quarter valued at $1,728,000. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NTLA. Wolfe Research upgraded shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price target on the stock in a research report on Monday, April 21st. Wedbush restated a "neutral" rating and issued a $10.00 price target on shares of Intellia Therapeutics in a research report on Monday, May 19th. Morgan Stanley lowered shares of Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. Chardan Capital restated a "buy" rating and issued a $68.00 price target on shares of Intellia Therapeutics in a research report on Friday, May 9th. Finally, Wells Fargo & Company decreased their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $36.90.

Intellia Therapeutics Trading Down 3.2%

NTLA stock traded down $0.30 during trading on Friday, hitting $9.16. 2,184,137 shares of the stock traded hands, compared to its average volume of 2,561,712. Intellia Therapeutics, Inc. has a one year low of $5.90 and a one year high of $28.18. The stock has a market cap of $948.82 million, a price-to-earnings ratio of -1.68 and a beta of 2.33. The company has a 50 day simple moving average of $7.98 and a 200 day simple moving average of $10.63.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.16. The firm had revenue of $16.63 million for the quarter, compared to the consensus estimate of $11.39 million. During the same period in the prior year, the business earned ($1.12) earnings per share. The company's revenue for the quarter was down 42.6% on a year-over-year basis. As a group, analysts predict that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.